PCV70 Comparative Cost-Effectiveness Analysis Of Catheter Directed Thrombolisys With Urokinase And Alteplase For Treatment Of Acute Peripheral Artery Disease  by Kostyuk, A. et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A141
Objectives: To explore the cost-effectiveness of clopidogrel as secondary preven-
tion in patients with a recent ischemic stroke (IS), or established peripheral arte-
rial disease (PAD) compared with aspirin in China. MethOds: A discrete event 
simulation was developed to evaluate the economic implications of secondary 
prevention with clopidogrel or aspirin, which are indicated for a patient with a 
recent MI, recent IS or established PAD. All available evidences were derived from 
clinical studies. Costs from Chinese health care perspective in 2013 US dollars 
and quality-adjusted life years (QALYs) were projected over a patient’s lifetime. 
Uncertainties were addressed using sensitivity analyses. Results: Compared with 
aspirin, clopidogrel yielded marginal life expectancy by 0.46 and 0.21 QALYs at 
an incremental cost-effectiveness ratio of $5,246 and $9,890 per QALY in patients 
with a recent IS and PAD, respectively. One-way sensitivity analyses showed evalu-
ation for patients with PAD and a recent IS was robust except the parameter of 
patient age. For the willingness to pay for $19,877 per QALY gained, clopidogrel 
intervention had a probability of 90% and 68% of being cost-effective for IS and 
PAD subgroups in comparison with aspirin, respectively. cOnclusiOns: The 
analysis suggests that clopidogrel for the secondary prevention is cost effective for 
patients with either PAD or a recent IS in the Chinese setting in comparison with 
aspirin.
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Objectives: Riociguat is the first product proven to improve health status in CTEPH 
patients. The objective of this study is to evaluate the cost-effectiveness of riociguat 
for patients with inoperable CTEPH or post-operative recurrent/persistent CTEPH in 
Turkey. MethOds: A Markov model taking transitions of patients between func-
tional classes and death state as core was adapted to Turkish setting. Turkish payer’s 
perspective was taken and time-horizon was set as patient’s lifetime (maximum 30 
years) broken into four-month cycles. Riociguat was compared to placebo and com-
mon off-label treatments within the model. Essential clinical inputs were derived 
from CHEST-1 and CHEST-2 trials and local resource-utilization data were conducted 
through an expert panel. The incremental cost-effectiveness ratios (ICER) were calcu-
lated per life-years (LYs) gained and sensitivity of the results was analyzed for all com-
parators and placebo in terms of key inputs. All costs were calculated in Turkish Liras 
(TL) and converted to USD using TL/USD currency rate as 2.1 (mid-2014). Results: 
Total cost of riociguat-treated patients is 1,558, 7,342 and 59,706 USD higher compared 
to bosentan, ambrisentan and sildenafil respectively and 74,227 USD lower compared 
to iloprost. Besides, riociguat is associated with increments of 1.0034, 1.0878, 1.8174 
and 1.8872 LYs compared to bosentan, ambrisentan, iloprost, sildenafil and placebo 
respectively. The ICER of riociguat per LYs gained compared to bosentan, ambrisentan, 
sildenafil and placebo were determined as 1,553 USD, 6,750 USD, 31,638 USD and 
39,553 USD correspondingly. Model is sensitive only to the changes in “the starting 
age of the disease”, yet not to an extent to affect the final results. cOnclusiOns: 
Riociguat is cost-effective for CTEPH treatment compared to bosentan, ambrisen-
tan, sildenafil and placebo with ICER values below the willingness-to-pay thresh-
old (3-times GDP per capita ─ 32,346 USD) for Turkey. Furthermore, riociguat is 
pharmacoeconomically dominant to iloprost with lower costs and higher clinical 
effectiveness.
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Objectives: The objective of this study was to compare the efficacy, complica-
tions, and costs associated with urokinase versus alteplase for the catheter-directed 
treatment of acute peripheral artery disease (APAD). MethOds: The cost-effec-
tiveness of catheter directed thrombolysis (CDT) with urokinase and alteplase for 
the treatment of APAD was compared using decision analysis. A literature-based 
decision model to evaluate cost-effectiveness was constructed. Successful treat-
ment outcomes were defined as clot lysis with a subsequent 30-day survival post-
treatment. Direct medical costs were assessed from the payer perspective in the 
Kazakhstan and analyzed using sensitivity analyses. A Monte Carlo analysis with 
1000 patients was performed to obtain mean and incremental cost-effectiveness 
ratios (ICERs). Results: The mean cost-effectiveness ratio was $148 463 per treat-
ment success for CDT with urokinase and $220 052 for CDT with alteplase. The ICER 
for alteplase relative to urokinase was $211 573 per additional CDT treatment suc-
cess. Approximately 75% of simulated cases indicated that alteplase was associated 
with increased costs and increased treatment success compared with urokinase. 
Also, when using alteplase higher risk of bleeding than with urokinase, this com-
plication is a major factor limiting the using of CDT. Results of a post hoc sensitivity 
analysis indicated that dominance decreased to approximately 10% of cases only 
under the most strict criteria. cOnclusiOns: Decision analysis found an ICER of 
$211 573 per additional CDT treatment success for alteplase relative to urokinase in 
the treatment of APAD from the perspective of the payer in the Kazakhstan. In about 
75% of cases resulting from a Monte Carlo simulation, alteplase was associated 
with increased costs and slightly increased CDT treatment success compared with 
urokinase, although this finding was sensitive to the distributional assumptions 
made concerning certain costs in the model.
were extracted from the RELY trial; utilities were derived from the literature. Costs 
for medications and procedures were obtained from official government databases, 
all costs were in 2014 Colombian pesos (1 USD = 2000.33 COP). Annual discount 
rate was 5% and we used a life time horizon (close to 20 years, on average). Cost-
effectiveness threshold was 3 times per capita GDP (around USD 22,500). Results: 
Compared with warfarin, patients treated with dabigatran 150 and 110 mg gained, 
on average 0.37 and 0.23 life-years, respectively, or 0.38 and 0.25 QALYs. The ICER for 
dabigatran 150 mg was USD 13,248 per QALY, and for dabigatran 110 mg was 23,621 
per QALY. cOnclusiOns: Dabigatran 150, compared with warfarin, the standard 
therapy, is cost-effective for ambulatory treatment of patients with non valvular AF. 
Dabigatran 110 ICER is discretely over the threshold (around 1000 USD).
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Objectives: To determine the economic value of dabigatran for stroke preven-
tion in atrial fibrillation (SPAF) compared to other reimbursed oral anticoagulants 
warfarin, rivaroxaban and apixaban from a perspective of Mexican public institu-
tions. MethOds: A Markov disease model with three month cycles length was 
developed. A number of clinically relevant events, including acute thromboembolic 
and bleeding events, as well as long-term consequences such as stroke, intracranial 
hemorrhage and acute myocardial infarction, were followed in the model within 
the lifetime horizon (mean 10 years from diagnosis for Mexican patients). Identical 
hypothetical cohorts of patients entered the model, following a disease background 
of atrial fibrillation (2500 simulations per treatment arm). Published results of head 
to head clinical trials or relative efficacy derived in network meta-analysis and indi-
rect comparisons were used to populate the model. Public institutional direct medi-
cal costs (2014 purchases and price tabulators) where retrieved to adopt the national 
health system perspective. Model outputs included total costs, event rates and 
life-years gained. Results: Mean life-years saved for dabigatran, apixaban, rivar-
oxaban and warfarin were 69.435, 69.219, 68.737 and 68.373 respectively. Estimated 
cost of treatment for dabigatran, warfarin, rivaroxaban and apixaban were 110,942 
USD, 108,757 USD, 124,718 USD and 112,373 USD, respectively. ICER showed that 
dabigatran is a cost-saving alternative versus rivaroxaban and apixaban, and a 
cost-effective one versus warfarin (defined by a one GDP per capita threshold in the 
country). These results where robust to changes in discount rates. cOnclusiOns: 
From a perspective of Mexican public institutions, the treatment with dabigatran 
was found to be cost-effective when compared with warfarin and economically 
dominant versus rivaroxaban and apixaban as it resulted in highest projected life 
years gained at lower costs.
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Objectives: Some high-risk CHD patients have poor outcomes with statin therapy 
and need to use combination regimens. The combination regimens have not been 
widely found in cost-effectiveness study. Therefore, this study aimed to analyze the 
cost-effectiveness of using Simvastatin, Atorvastatin, and Atorvastatin-Ezetimibe 
combination among high-risk CHD outpatients. MethOds: A cross-sectional ret-
rospective study for 12 months (April 1, 2013 to April 1, 2014) in high-risk CHD out-
patients was performed at the Chandrubeksa Hospital Medical Department of the 
Royal Thai Air Force, Nakhon Pathom, Thailand. The incremental cost-effectiveness 
ratio (ICER) was determined for cost-effectiveness analysis. The direct medical costs 
were computed by micro-costing method (Reference price in 2014). The effective-
ness outcomes were the percentage differences in LDL-C reduction and the pro-
portion of patients achieving treatment goals (Standard goal (LDL-C < 100 mg/dL) 
and Aggressive goal (LDL-C < 70 mg/dL)). The cost-effectiveness was concerned on 
the provider perspective. Results: There were differences of the direct medical 
costs between three groups (median ± IQR: 517 ± 149.7, 3,910.4 ± 3,326.5, 13,733.7 
± 3,350.0; p 0.0001, respectively). Simvastatin regimen had the lowest percentage 
differences in LDL-C reduction when compared to other groups (mean ± SD ; -20.1 
± 30.1, -28.3 ± 24.2, -38.1 ± 17.1; p 0.0001, respectively). Atorvastatin regimen provide 
the best cost-effectiveness (ICER = 346.4 THB) by using the proportion achieved 
standard treatment goal, while Atorvastatin-Ezetimibe combination was dominated. 
In the case of the aggressive treatment goal showed that Atorvastatin-Ezetimibe 
combination regimens provided the most cost-effectiveness (ICER 437.7 THB and 
1,189.8 THB, respectively). cOnclusiOns: Comparison treatment with Simvastatin, 
Atorvastatin and Atorvastatin-Ezetimibe combination among high-risk CHD out-
patients showed that Atorvastatin was more effectiveness and less costly than 
Atorvastatin-Ezetimibe combination in term of standard treatment goal. While 
Atorvastatin-Ezetimibe combination was an interesting option when aggressive 
treatment goal was used.
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6 months. The incremental cost-effectiveness ratio (ICER) was determined for 
the cost-effectiveness analysis and comparisons of the three groups with inten-
sive doses (Simvastatin 40 mg/day and Atorvastatin 20-40 mg/day monotherapy 
or combination therapy with Ezetimibe 10 mg) on the provider perspective. The 
direct medical costs were computed by micro-costing method (Reference price in 
2014). The effectiveness was determined by the percentage differences in LDL-C 
reduction. Results: From 250 patients with high risk CHD treated by inten-
sive doses. Sixty-seven, 145 and 38 patients took Simvastatin, Atorvastatin and 
Atorvastatin-Ezetimibe combination, respectively. The outcome determined by the 
percentage differences LDL-C reduction showed that Simvastatin had the lowest 
effectiveness comparing to other groups (mean ± SD; -13.8 ± 32.3%, -28.0 ± 24.8%, 
and -37.8 ± 17.2%, p 0.0001 respectively). ICER determination showed that the 
intensive doses treatment of Atorvastatin had the best result (ICER = 326.91 THB) 
whereas than of Atorvastatin-Ezetimibe combination was poorer (ICER = 732.44 
THB). cOnclusiOns: Comparison of intensive doses Simvastatin, Atorvastatin, 
and Atorvastatin-Ezetimibe combination regimens in second-line treatment 
among high-risk CHD outpatients showed that intensive dose Atorvastatin regi-
men was the most cost-effectiveness.
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Objectives: Utilizing previously published selection criteria1, identify and evaluate 
current literature that is focused on cost-effectiveness of genotype-guided medica-
tion programs for patients at high risk for a thrombotic event. The aim of study is 
to provide the scientific community with a comprehensive, yet brief overview of 
studies that could inform future development of personalized medicine research 
within this subset of cardiovascular disease. MethOds: The literature search was 
conducted within PubMed and Web of Science databases. The objective was to iden-
tify studies published from January 2008 (conclusion period of Vegtar’s research) to 
October 2014 that also included the search term “pharmacogenetic” and the term 
“pharmacoeconomic”. Results: Ten articles met inclusion criteria. Genotypes 
CYP2C19, CYP2C9, VKORC1, KIF6 were used alone and/or in combination within 
differing patient populations. Medication programs included (number of papers): 
Warfarin (4), Clopidgrel (including other in-class agents: 2), phenprocoumon (1), 
atorvastatin/pravastatin (1) and Dabigitran (and other in-class agents: 1). The fol-
lowing types of economic evaluations were utilized either alone or in combination: 
CEA, CUA, CUR, CBA, Threshold Analysis, ICER, ICUR, EA, and INB. Outcome meas-
ures and sensitivity analysis were variable and did not always reach thresholds of 
significance within the overall study population. cOnclusiOns: Comprehensive 
study evaluations were lacking due to inconsistent methodology. Specific study 
guidelines for the field of genotype-guided therapy are needed. With multiple block-
buster medications reaching patent expiry, the cost-effectiveness and sensitivity 
analysis from previous years warrant a second evaluation. It is anticipated that 
genotype-guided treatment may be shifting to a cost-effective option for only the 
treatment-resistant, or smaller populations with a differentiated risk status. This is 
in contrast to selecting genotype-driven therapy as an initial option for the masses 
of patients diagnosed with thrombotic event risk in a more traditional “treat every-
one the same” algorithm. 1Stepfan Vegter et. al, “Pharmacoeconomic Evaluations 
of Pharmacogenetic and Genomic Screening Programmes” Pharmacoeconomics 
2008: 26(7) 569-587.
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Objectives: To assess cost effectiveness of anticoagulant clinics after FDA approval 
of New Oral Anticoagulants (NOACs) for preventing of ischemic stroke in Atrial 
Fibrillation (AF) patients in the United States. MethOds: A decision tree was built 
using outcomes data obtained from randomized clinical trials and publicly available 
cost data. The analysis compared the cost effectiveness of 150mg dabigatran twice 
a day taken with no anticoagulation clinic monitoring versus warfarin titrated to 
dose based upon anticoagulation clinic monitoring. The analysis was for one year 
using an institutional perspective. The population in this analysis was a cohort of 
AF patients, ≥ 65 years old, with a mean CHADS2 score of 2, and no contraindication 
to anticoagulation. The primary outcomes measured were cost in US$ and Quality 
Adjusted Life Year (QALY). All data were subject to sensitivity analyses. Results: 
The base case analysis showed that changing from warfarin to dabigatran without 
monitoring resulting in an additional $251,000 per QALY saved. Sensitivity analyses 
found that the model was sensitive to utilities assigned to outcomes and the prob-
ability of death. cOnclusiOns: NOACs claim to reduce the need for anticoagula-
tion monitoring, thereby competing with anticoagulation clinics. This study showed 
that substituting NOACs for warfarin in this population was not within acceptable 
willingness to pay values for new therapies. It is likely that anticoagulation clinics 
will remain a cost effective option in the near future.
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bAcKGROund: Atrial fibrillation (AF) is associated with development of thrombo-
embolic events [1]. The standard therapy used in patients with non-valvular atrial 
fibrillation (NVAF) with risk of stroke is Warfarin. There are new oral anticoagulants 
(NOACs) that also are recommended [2]. Objectives: Evaluate cost-effectiveness 
of Apixaban compared to Oral Anticoagulants in the prevention of thromboembo-
litic events in NVAF patients from perspective of Guatemala’s Public HealthCare 
System (IGSS). MethOds: A Markov decision-analysis model was designed using 
data from clinical trials [3,4,5] (indirect comparisons, where appropriate) to evaluate 
lifetime costs and quality-adjusted life-years (QALY) of Apixaban (5mgBID) in com-
parison to Rivaroxaban (20mg/day) and Warfarin (5mg/day). IGSS used Warfarin and 
Rivaroxaban in NVAF patients. The health states evaluated were: ischemic and hem-
orrhagic strokes, hemorrhagic events (intracranial hemorrhage, other major bleeds 
and clinically relevant non major bleeds), systemic embolism (SE) and myocardial 
infarction (MI). The model population was a hypothetical cohort of 70-year-old NVAF 
patients, suitable to Vitamin K antagonist treatment. Only direct medical costs were 
considerate and taken from IGSS databases from 2014 [6,7]. Outcomes were: overall 
cost, QALY and ICER.  Cost and health outcomes were discounted at 5.0% per year, 
using a lifetime horizon. Results: Apixaban is the only therapy that prevents and 
improved all clinical outcomes. Apixaban prevented: 3 Ischemic Strokes, 14 hemor-
rhagic strokes, 71 hemorrhagic events, 1 MI and 3 SE in comparison to Warfarin. 
Overall costs in a lifetime period per patient were US$9,190; US$11,763; US$12,045 
for Warfarin, Apixaban, and Rivaroxaban respectively.  Apixaban earned the high-
est QALY 5.740; Rivaroxaban reported 5.699 and Warfarin 5.570. Used Warfarin as a 
base, the ICER of Apixaban and Rivaroxaban were US$15,135 and US$21,961 respec-
tively. cOnclusiOns: Neither Apixaban nor Rivaroxaban are Cost-Effectiveness 
therapies in comparison with Warfarin according Guatemala’s 3GPB (US$10,400). 
Among the NOACs currently used by IGSS, Apixaban is shown to be a cost-saving 
therapy in comparison to Rivaroxaban.
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Objectives: To assess the cost-effectiveness of apixaban for the prevention of 
stroke in patients with non valvular atrial fibrillation (NVAF) from the payer’s 
perspective of the Ministry of Public Healthcare in Ecuador (MPHE). MethOds: A 
lifetime Markov model was developed to evaluate the pharmacoeconomic impact 
of apixaban compared to aspirin, warfarin, dabigatran in different dosage (110 
mg and 150 mg) and rivaroxaban, in patients with NVAF and risk of stroke. The 
clinical events considered were: stroke, bleeding, myocardial infarction (MI), car-
diovascular hospitalization (CVH), and treatment discontinuation (TD) of which 
the data was obtained from indirect comparisons, published literature and input 
data from a local expert panel. All costs information 2014 (drug and adverse events) 
was obtained from public data sources of the MPHE. Results: In a Cohort of 
1000 patients with NVAF, apixaban avoided 51 ischemic stokes and 3 bleedings 
vs. aspirin, 4 ischemic stokes, 28 bleedings and 11 related deaths vs. warfarin, 
21 ischemic stokes and 4 related deaths vs. dabigatran 110mg, and 11 ischemic 
strokes, 28 bleedings and 5 related deaths vs. dabigatran 150mg and 7 ischemic 
stokes, 7 bleedings and 6 related deaths vs. rivaroxaban. Apixaban was associated 
with 0.324 life years (LYG) and 0.0.273 quality-adjusted life-years (QALYs) gain 
when compared to aspirin, 0.181 LYG and 0.190 QALYs gain compared to warfarin, 
0.123 LYG and 0.106 QALYs gain when compared to dabigatran 110mg, 0.081 LYG 
and 0.07 QALYs gained compared to dabigatran 150mg and 0.059 LYG and 0.048 
QALYs gained compared to rivaroxaban. Apixaban was more effective and less 
costly (dominant) than dabigatran 110mg and dabigatran 150mg and cost-effective 
alternative compared with aspirin, warfarin and rivaroxaban. cOnclusiOns: 
Apixaban is a cost effective or dominant alternative compared with treatment 
options for the prevention of stroke in patients with NVAF from the payer’s per-
spective of the Ecuadorian Ministry of public healthcare.
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Objectives: Current studies have recommended intensive doses of statins in 
patients with diabetes or cardiovascular disease. In general practice, standard 
dose statins, which used to be effective treatment may not be good enough. 
Furthermore, the cost-effectiveness studies have not concerned about this prob-
lem that may be an important factor in cost-effectiveness analysis. The pur-
pose of this study was to determine the cost-effectiveness of intensive doses of 
Simvastatin, Atorvastatin, and Atorvastatin-Ezetimibe combination among high-
risk CHD outpatients in second-line treatments. MethOds: A cross-sectional ret-
rospective study in high-risk CHD outpatients was performed at the Chandrubeksa 
Hospital Medical Department of the Royal Thai Air Force, Thailand. Data collection 
was done by computerization combined with reviewing medical record during 
